• Medicine Name - Bracanat
  • API - Olaparib
  • Packaging - Tablets
  • Strength - 100 mg, 150 mg

What is Olaparib, and what it is used for:

Olaparib is a non-chemotherapy oral medication that may give a different option in the treatment of certain types of cancer. As a poly (ADP-ribose) polymerase (PARP) inhibitor, it is used for:

First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer: Olaparib is used for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in full or partial response to first-line platinum-based chemotherapy.

First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer Along with Medicine Bevacizumab: Olaparib is used along with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in full or partial response to 1`st-line platinum-based chemo and whose cancer is linked with HRD+ve status defined by either a deleterious/suspected deleterious BRCA mutation and/or genomic instability.

Maintenance Treatment of Recurrent Ovarian Cancer: Olaparib is used for the maintenance treatment of adult patients with a recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.

Advanced Germline BRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy: Olaparib is used to treat adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been previously taken treatment with 3 or more chemotherapy.

Germline BRCA-mutated HER2-negative Metastatic Breast Cancer: Olaparib is used to treat adults with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have taken treatment with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR+ve breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.

First-Line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Adenocarcinoma: Olaparib is used for the maintenance treatment of adults with deleterious/suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose condition has not progressed on minimum 16 weeks of a 1`st-line platinum-based chemo regimen.

HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer: Olaparib is used to treat adults with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following earlier treatment with medicine enzalutamide or abiraterone.

Olaparib Dosage

The recommended dosage is 300 mg by mouth orally twice daily with or without food. Patients receiving Olaparib 150 mg tablets for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. For moderate renal impairment (CLcr 31-50 mL/min), reduce Olaparib dosage to 200 mg by mouth twice daily.

Take Olaparib by mouth 2 times daily. Each dose must be taken approximately 12 hours apart. Swallow tablets whole. Do not crush, chew, dissolve, or divide the pills. Take tablets with or without food exactly as your healthcare provider tells you. Do not take excess than 4 tablets in a single day.

Taking Olaparib for early breast cancer and have hormone receptor-positive disease, continue to take hormonal therapy throughout your treatment with Olaparib.

Taking Olaparibfor for prostate cancer and receiving gonadotropin-releasing hormone (GnRH) analog therapy, continue with this treatment throughout your treatment with Olaparib unless you have had a surgery to scale down the existence of testosterone in the body (surgical castration).

If you miss/skip a dose of Olaparib, take your very next dose at about usual scheduled time. Do not take an aditional dose to make up for a missed/skipped dose. If you take excess Olaparib, call your healthcare professional or go to the nearest hospital emergency room promptly.

Olaparib side effects

The most commonly reported side effects with Olaparib as a single agent include: vomiting, nausea, fatigue, anemia, diarrhea, decreased appetite, cough, headache, neutropenia, abdominal pain upper, dysgeusia, dyspnea, dizziness, dyspepsia, leukopenia, and thrombocytopenia.

Side effects of Olaparib in combination with bevacizumab were fatigue, nausea, anemia, lymphopenia, diarrhea, vomiting, neutropenia, urinary tract infection, leukopenia, and headache.

Warnings And Precautions
  • Do not initiate treatment with lynparza 150 mg tablets until patients have recovered from the hematological toxicity caused by prior chemotherapy. Monitor complete blood count (CBC) for cytopenia at baseline and on monthly basis thereafter for clinically significant changes during treatment.
  • For prolonged hematological toxicities, interrupt treatment and monitor blood counts on weekly basis until recovery. In case the levels have not recovered to Grade-1 or less after four weeks, the respective patient should be referred to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS or AML is confirmed, discontinue therapy.
  • For patients with various cancers who received Olaparib treatment as a single agent, the incidence of pneumonitis, including fatal cases, was reported. If new or worsening respiratory symptoms such as cough, dyspnea, fever, or a radiological abnormality occur, interrupt treatment and promptly evaluate the source of the signs/symptoms. If pneumonitis is confirmed, discontinue treatment and treat the patient appropriately.
  • Several thromboembolic events, including pulmonary embolism, may occur in patients with metastatic castration-resistant prostate cancer who take lynparza 100 mg tablets plus androgen deprivation therapy. Monitor patients for signs/symptoms of venous thrombosis and pulmonary embolism and treat as medically required, which may include long-term anticoagulation as clinically mentioned.
  • Olaparib can be responsible for causing fetal harm when administered to a pregnant woman on behalf of its mechanism of action and findings in animals. Respective females of reproductive age/potential should use appropriate contraception throughout treatment and for six months following the final dose of Olaparib.
  • No information is available regarding the existence of olaparib in human milk, or its effects on the breastfed child or on milk production. Because of the potential for severe side effects in the breastfed child from lynparza olaparib, lactating women should not breastfeed during treatment with this medicine and for 1-onth after receiving the final dose.
Storage and Handling

Olaparib is supplied as 150 mg and 100 mg tablets. Store at 20 to 25°C (68 to 77°F), excursions permitted to 15 to 30°C (59 to 86°F). Store these tablets in the original bottle in order to protect them from moisture.

Drug Interactions of Abacavir Sulfate
  • Coadministration of CYP3A inhibitors can increase the concentrations of Olaparib, which may increase the risk for side effects. Coadministration of strong/moderate CYP3A inhibitors is not recommended. If the strong/moderate inhibitor must be coadministered, reduce the dosage of Olaparib.
  • Concomitant use with a strong/moderate CYP3A inducer decreased olaparib exposure, which may reduce the efficacy of Olaparib. Coadministration of strong/moderate CYP3A inducers is not recommended.

Commonly asked questions:

Olaparib is a targeted medicine. It is widely used for the treatment of breast cancer, ovarian cancer, prostate cancer, fallopian tube cancer, pancreatic cancer, and peritoneal cancer.

This medicine is supplied in a couple of dosage strengths, which are as follows:

  • Olaparib 100 mg Tablets
  • Olaparib 150 mg Tablets

Olaparib comes in 150 mg and 100 mg tablets for oral administration.

Olaparib is a non-chemotherapy oral medicinal product that may give you and your doctor a different option in the treatment of certain types of cancer.

You can buy olaparib online from any authorized wholesaler after getting a prescription from a qualified doctor. It is always better to check the credential of the wholesaler/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

Olaparib is a pharmaceutical medicine that can be legally dispensed against a valid medical prescription. The medicine can be made available through a wide network of authorized distributors in India. (Delhi, Ahmedabad, Mumbai, Hyderabad, Kolkata, Chennai, Bangalore, and Pune etc.) IKRIS Pharma Network (IPN) can help to get Olaparib Tablets.

The Olaparib 100mg/150mg cost in India is less and can vary. If you are looking to buy this medicine online at the best price from India, then IKRIS Pharma Network (IPN) can be your one-stop solution.

Patients can simply fill the order form or can send mail to info@ikrispharmanetwork.com. Patients can also send WhatsApp messages to +91 8130290915 or can dial TOLL-FREE Number: 18008891064. We will reply ASAP with the details of the Olaparib price as well as the procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription from the Clinician.


All Trademarks and Brands that appear on the website belong to their respective owners and Ikris Pharma Network does not lay any claim on them we only provide Information. We are NOT an ONLINE store and We do not sell Narcotics and Sedatives. Olaparib is a pharmaceutical drug that legally requires a medical prescription to be dispensed. The following information is meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, generics, brands, Cooperate Sourcing, reseller, and Pharmacies.